Abbvie Inc ABBV

$291.31 +3.07 (1.07%)

Valuation

Market cap
514,924,192,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
P/E (trailing)
22.47
P/E (forward)
20.60
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
5,041,100
Avg volume
4,907,258
Day's range
$281.07 – $291.73
Shares out
1,767,616,000
Stochastic %K
47%
Beta
0.20
Analysts
Moderate Buy
Price target
$305.93

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

RichboyZan Nov 9, 10:33 AM
$ABBV Maybe this is just a difficult part of the journey
0 replies
55X_ROI_Q1_2026 Nov 8, 11:53 PM
$SLS $ABVX First Remission (CR1) Median Overall Survival Absent Transplant BAT/ SOC is Onureg / ORAL AZ - MOS is 24.7 MONTHS* -- Adding Venetoclax to Oral AZ Failed to Increase MOS in 5 Large Trials, including 2 Phase 3 Trials, conducted by $ABBV for AML Remission • VIALE-M Failed in First Remission Transplant Ineligible AML • VIALE-T Failed in Post Transplant Maintenance Dr. Kantarjian of MD ANDERSON, Published Data showing ADDING Venetoclax to Oral AZ for First Remission - MOS OF JUST 18.6 months. *GPS has proven effective in Preventing Relapse and Extending Survival in ALL Previous Trials INCLUDING In 2 Phase 2 Trials for AML REMISSION PATIENTS Ineligible for Transplant --- •• With a MOS > 67.6 Months in FIRST REMISSION // 67.6 vs BAT 24.7 • 21 Month MOS in Second Remission / Stat Sig, all MRD+ and Older who got less Gps immunotherapy - just 12 doses in Year 1 vs 15 Y1 doses and extended beyond in the REGAL P3. // //
0 replies
55X_ROI_Q1_2026 Nov 8, 7:20 PM
$SLS $ABVX $MRNA First Remission Median Overall Survival Absent Transplant BAT/ SOC is Onureg / ORAL AZ - MOS is 24.7 MONTHS* -- Adding Venetoclax to Oral AZ Failed to Increase MOS in 5 Large Trials, including 2 Phase 3 Trials, conducted by $ABBV for AML Remission • VIALE-M Failed in First Remission Transplant Ineligible AML • VIALE-T Failed in Post Transplant Maintenance Dr. Kantarjian of MD ANDERSON, Published Data showing ADDING Venetoclax to Oral AZ for First Remission - MOS OF JUST 18.6 months. *GPS has proven effective in Preventing Relapse and Extending Survival in ALL Previous Trials INCLUDING In 2 Phase 2 Trials for AML REMISSION PATIENTS Ineligible for Transplant --- •• With a MOS > 67.6 Months in FIRST REMISSION // 67.6 vs BAT 24.7 • 21 Month MOS in Second Remission / Stat Sig, all MRD+ and Older who got less Gps immunotherapy - just 12 doses in Year 1 vs 15 Y1 doses and extended beyond in the REGAL P3.
0 replies
focafoca99 Nov 8, 5:55 PM
$ABBV announced strong patient-satisfaction results from two Phase 4 aesthetic studies in GLP-1 users. https://www.rapidticker.com/news/abbv-allergan-aesthetics-reports-improved-satisfaction-f1fb2
0 replies
TopOptionsAIerts Nov 8, 9:25 AM
$ABBV NOV20 300C · in play Zone: $289.27 to $293.35 Invalidation: close under $287.71 Objectives: $298.74, then $302.93 The math: up 2.6% to the first objective and 4.0% to the second, against 1.2% risk on the invalidation, about 2.1 to 1 to the first and about 3.2 to 1 to the second. I like this swing because Friday flushed to $281.07 and still closed at $291.31, up 1.1% on the day, one session after tagging $302.93. You are buying the bounce off the washout, not chasing the spike, and $287.71 is the line where you are wrong so the risk is set before the move starts. The Q3 print backs it up, with Skyrizi up 22.7% and the full year guide raised, and $298.74 is the first spot where sellers have to prove it again. Watch: $298.74, the October 30 high. A close over it opens the run toward $302.93.
0 replies
GTA_Terminal Nov 8, 8:17 AM
$ABBV Options Flow Leans to Puts: A Smart-Money Check on the Stock. It's down about 1% from a week ago. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=ABBV&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=ABBV Read the full article for the full details: https://globaltradersacademy.com/articles/abbvie-abbv-options-flow-turns-bearish-a-smart-money-check-on-the-stock?utm_source=stocktwits&utm_medium=social
0 replies
openclassaction2 Nov 8, 7:05 AM
$ABBV a drug people refill every month is an end customer you can point to. seems like the ai build never found one of those, just tenants billing tenants, and refills do not need a data center
1 replies
lextrading Nov 7, 8:16 PM
$ABBV The stock is approaching a key long-term resistance. According to FAST Graphs, the stock is nearing significant long-term valuation highs, levels at which investors have historically taken profits. -------------------------- FAST Graphs is exceptional for visualizing fundamental trends. Instead of digging through endless tables, you get a clean, evidence‑based picture of valuation, earnings, and long‑term performance. I’ve partnered with FAST Graphs to extend a 25% discount on subscriptions. Use code: AFFILIATE25 👉 fastgraphs.com/?ref=kevinqi
1 replies